The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Industries Direct’s proprietary databases, Astion Pharma A/S’s corporate website, SEC filings, investor presentations and featured press releases, both from Astion Pharma A/S and market -specific third party sources, put together by Global Industries Direct’s team.

Scope of the Research

- Astion Pharma A/S - Brief Astion Pharma A/S overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Astion Pharma A/S human therapeutic division.
- Detailed Analysis of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Astion Pharma A/S with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Astion Pharma A/S’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Why Should You Get This Report?

- Evaluate Astion Pharma A/S’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Astion Pharma A/S in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Astion Pharma A/S’s Research and Development portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Astion Pharma A/S.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Astion Pharma A/S and identify potential opportunities in those areas.

Table Of Contents

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Astion Pharma A/S Snapshot 5
Astion Pharma A/S Overview 5
Key Information 5
Key Facts 5
Astion Pharma A/S - Research and Development Overview 6
Key Therapeutic Areas 6
Astion Pharma A/S - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Astion Pharma A/S - Pipeline Products Glance 10
Astion Pharma A/S - Late Stage Pipeline 10
Phase III Products/Combination Treatment Modalities 10
Astion Pharma A/S Clinical Stage Pipeline Products 11
Phase II Products/Combination Treatment Modalities 11
Phase I Products/Combination Treatment Modalities 12
Astion Pharma A/S - Early Stage Pipeline Products 13
Pre-Clinical Products/Combination Treatment Modalities 13
Astion Pharma A/S - Drug Profiles 14
ASF-1057 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
ASF-1085 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
ASF-1096 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
ASF-1097 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
ASF-1102 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
Astion Pharma A/S - Pipeline Analysis 19
Astion Pharma A/S - Pipeline Products by Therapeutic Class 19
Astion Pharma A/S - Pipeline Products by Route of Administration 20
Astion Pharma A/S - Pipeline Products by Molecule Type 21
Astion Pharma A/S - Dormant Projects 22
Astion Pharma A/S - Locations And Subsidiaries 23
Head Office 23
Financial Deals Landscape 24
Astion Pharma A/S, Deals Summary 24
Astion Pharma A/S, Pharmaceuticals and Healthcare, Deal Details 25
Venture Financing 25
Astion Pharma Raises US$ 6.5 Mln In Venture Financing 25
Appendix 26
Methodology 26
Coverage 26
Secondary Research 26
Primary Research 27
Expert Panel Validation 27
Contact Us 27
Disclaimer 27

List of Tables

Astion Pharma A/S, Facts and Figures 5
Astion Pharma A/S, Key Facts 5
Astion Pharma A/S - Pipeline by Therapy Area and Indication, H2 2011 7
Astion Pharma A/S - Pipeline by Stage of Development, H2 2011 8
Astion Pharma A/S - Monotherapy Products in Pipeline, H2 2011 9
Astion Pharma A/S - Phase III, H2 2011 10
Astion Pharma A/S - Phase II, H2 2011 11
Astion Pharma A/S - Phase I, H2 2011 12
Astion Pharma A/S - Pre-Clinical, H2 2011 13
Astion Pharma A/S - Pipeline By Therapeutic Class, H2 2011 19
Astion Pharma A/S - Pipeline By Route of Administration, H2 2011 20
Astion Pharma A/S - Pipeline By Molecule Type, H2 2011 21
Astion Pharma A/S - Dormant Developmental Projects, 2010 22
Astion Pharma A/S, Deals Summary 24
Astion Pharma Raises US$ 6.5 Mln In Venture Financing 25

List of Figures

Astion Pharma A/S - Pipeline by Therapy Area and Indication, H2 2011 7
Astion Pharma A/S - Pipeline by Stage of Development, H2 2011 8
Astion Pharma A/S - Monotherapy Products in Pipeline, H2 2011 9
Astion Pharma A/S - Pipeline By Therapeutic Class, H2 2011 19
Astion Pharma A/S - Pipeline By Route of Administration, H2 2011 20

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

Diagnostics and Therapeutics for HIV: Global Markets

Diagnostics and Therapeutics for HIV: Global Markets

  • $ 6 650
  • Industry report
  • April 2014
  • by BCC Research

STUDY GOALS AND OBJECTIVES The aim of this report is to provide detailed market, technology and industry analyses to help readers quantify and qualify the market for products used in the treatment, testing ...

JAK and PI3K Signaling Pathway Markets

JAK and PI3K Signaling Pathway Markets

  • $ 6 650
  • Industry report
  • April 2014
  • by BCC Research

REPORT HIGHLIGHTS The global market for signal transduction therapies/inhibitors (JAK and PI3K) reached $173.5 million in 2012. This market is expected to grow to $464.5 million in 2013 and $2.2 billion ...

Therapeutics for Women%s Health: Technologies and Global Markets

Therapeutics for Women%s Health: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • May 2014
  • by BCC Research

Use this report to: - Learn about the main women's health disorders and relevant disease prevalence population. - Identify the impact of demographic, economic, and other factors that will drive future ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.